Harvey E. Finkel, M.D. (Associate); William J. Yount, M.D.
This content is PDF only. Please click on the PDF icon to access.
Among malignant lymphoreticular tumors, reticulum cell sarcoma is the least responsive to therapy. The course of this disease is usually one of inexorable progression. Alkylating agents, vinblastine, and irradiation have been used extensively; however responses are not frequent, and are often incomplete and transient.
Vincristine is known to possess activity against reticulum cell sarcoma; unfortunately treatment must often be stopped because of neurotoxicity. In an attempt to avoid severe toxicity while maintaining good therapeutic responses, we have used vincristine in small doses (as low as 5 µg/kg biweekly).
Six patients with histologically confirmed, far advanced disease and resistance to other
Finkel HE, Yount WJ. Low Dose Vincristine Therapy of Reticulum Cell Sarcoma.. Ann Intern Med. ;64:1164. doi: 10.7326/0003-4819-64-5-1164_2
Download citation file:
Published: Ann Intern Med. 1966;64(5):1164.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use